Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Single Intraoperative Administration of CA-008 in Subjects Undergoing Unilateral Transpositional First Metatarsal Osteotomy for the Correction of Hallux Valgus Deformity

Next Previous
Trial Profile

A Phase 1/Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Single Intraoperative Administration of CA-008 in Subjects Undergoing Unilateral Transpositional First Metatarsal Osteotomy for the Correction of Hallux Valgus Deformity

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vocacapsaicin (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Concentric Analgesics

Most Recent Events

  • 11 Sep 2018 According to a Concentric Analgesics media release, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to CA-008 for post-surgical pain, decision was supported by data from this study.
  • 16 Jul 2018 Status changed from active, no longer recruiting to completed.
  • 14 May 2018 According to a Concentric Analgesics media release, the company anticipates presenting complete data, including pharmacokinetics and full 28-day follow-up results, from the trial later in 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top